Isabelle Carrière1, Thibault Mura2, Karine Pérès3, Joanna Norton2, Isabelle Jaussent2, Arlette Edjolo3, Olivier Rouaud4, Claudine Berr2, Karen Ritchie5, Marie Laure Ancelin2. 1. INSERM U1061, Montpellier, France; Université Montpellier I, U1061, Montpellier, France. Electronic address: isabelle.carriere@inserm.fr. 2. INSERM U1061, Montpellier, France; Université Montpellier I, U1061, Montpellier, France. 3. INSERM ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France; Université Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France. 4. CHRU Dijon, Centre Mémoire Ressources et Recherche, Dijon, France. 5. INSERM U1061, Montpellier, France; Université Montpellier I, U1061, Montpellier, France; Faculty of Medicine, Imperial College, London, United Kingdom.
Abstract
OBJECTIVE: To examine the cross-sectional and longitudinal associations between benzodiazepine use and daily activity limitations, according to drug indications and duration of action. DESIGN: Prospective cohort study. SETTING: Population-based three-city study. PARTICIPANTS: 6,600 participants aged 65 years and over included between 1999 and 2001 and followed after 2, 4, and 7 years. MEASUREMENTS: Benzodiazepine users were separated into hypnotic, short-acting anxiolytic, and long-acting anxiolytic users and compared with non users. Three outcomes were examined assessing restrictions in mobility, instrumental activities of daily living (IADLs) and social participation. RESULTS: In multivariate simple or mixed logistic models adjusted for sociodemographic variables, impairments and comorbidity, and for anxiety, insomnia, and depression, hypnotic benzodiazepines were moderately associated with mobility limitation prevalence and IADL limitation incidence. Short-acting and long-acting anxiolytics were associated with IADL limitation prevalence and with mobility limitation prevalence and incidence and long-acting anxiolytics were also associated with IADL limitation incidence. Chronic benzodiazepines users were at a marked risk of developing restrictions for the three outcomes; odds ratio: 1.71 (95% CI: 1.23-2.39) for mobility, 1.54 (95% CI: 1.14-2.10) for IADL, and 1.74 (95% CI: 1.23-2.47) for participation limitations. CONCLUSIONS: Benzodiazepine users are at increased risk of activity limitations regardless of the duration of action or indication. Chronic use of benzodiazepines should be avoided in order to extend disability-free survival.
OBJECTIVE: To examine the cross-sectional and longitudinal associations between benzodiazepine use and daily activity limitations, according to drug indications and duration of action. DESIGN: Prospective cohort study. SETTING: Population-based three-city study. PARTICIPANTS: 6,600 participants aged 65 years and over included between 1999 and 2001 and followed after 2, 4, and 7 years. MEASUREMENTS: Benzodiazepine users were separated into hypnotic, short-acting anxiolytic, and long-acting anxiolytic users and compared with non users. Three outcomes were examined assessing restrictions in mobility, instrumental activities of daily living (IADLs) and social participation. RESULTS: In multivariate simple or mixed logistic models adjusted for sociodemographic variables, impairments and comorbidity, and for anxiety, insomnia, and depression, hypnotic benzodiazepines were moderately associated with mobility limitation prevalence and IADL limitation incidence. Short-acting and long-acting anxiolytics were associated with IADL limitation prevalence and with mobility limitation prevalence and incidence and long-acting anxiolytics were also associated with IADL limitation incidence. Chronic benzodiazepines users were at a marked risk of developing restrictions for the three outcomes; odds ratio: 1.71 (95% CI: 1.23-2.39) for mobility, 1.54 (95% CI: 1.14-2.10) for IADL, and 1.74 (95% CI: 1.23-2.47) for participation limitations. CONCLUSIONS:Benzodiazepine users are at increased risk of activity limitations regardless of the duration of action or indication. Chronic use of benzodiazepines should be avoided in order to extend disability-free survival.
Authors: Rachel D Maree; Zachary A Marcum; Ester Saghafi; Debra K Weiner; Jordan F Karp Journal: Am J Geriatr Psychiatry Date: 2016-06-07 Impact factor: 4.105
Authors: Ji Hyun An; Mi Jin Park; Maurizio Fava; David Mischoulon; Hyewon Kim; Jihoon Jang; Jin Pyo Hong; Jun Sang Park; Hong Jin Jeon Journal: Front Psychiatry Date: 2020-05-19 Impact factor: 4.157